Product Description
TE-8105 is an ultralong-acting human GLP-1 receptor agonist (peptide segment #7-37 of native human GLP-1), in which alanine at position #8 is replaced by 2-aminoisobutyric acid and lysine at position #26 lysine is conjugated with a fatty acid bundle containing 2 long-chain fatty acids, a C16 acid and a C18 diacid. TE-8105 has been compared with semaglutide, which is modified with one C18 diacid at #26 lysine residue, for various effects. (Sourced from: https://www.immunwork.com/article.php?lang=en&tb=3&id=207)
Mechanisms of Action: GLP-1 Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Immunwork, Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Obesity|Overweight
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TE-8105-101 | P1 |
Recruiting |
Obesity|Overweight |
2025-09-27 |